GLUE Quote, Financials, Valuation and Earnings

CEL-SCI Corp. has a net margin of -212.1% compared to Monte Rosa Therapeutics, Inc.'s net margin of --. Monte Rosa Therapeutics, Inc.'s return on equity of 8.6% beat CEL-SCI Corp.'s return on equity of -266.61%.

Monte Rosa Therapeutics, Inc. has a consensus price target of $22.70, signalling upside risk potential of 28.69%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 808.12%. Given that CEL-SCI Corp. has higher upside potential than Monte Rosa Therapeutics, Inc., analysts believe CEL-SCI Corp. is more attractive than Monte Rosa Therapeutics, Inc..

Monte Rosa Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

Monte Rosa Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Monte Rosa Therapeutics, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

Monte Rosa Therapeutics, Inc. quarterly revenues are $12.8M, which are larger than CEL-SCI Corp. quarterly revenues of --. Monte Rosa Therapeutics, Inc.'s net income of -$27.1M is lower than CEL-SCI Corp.'s net income of -$5.7M. Notably, Monte Rosa Therapeutics, Inc.'s price-to-earnings ratio is 57.76x while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Monte Rosa Therapeutics, Inc. is 7.51x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Mirum Pharmaceuticals, Inc. has a net margin of -212.1% compared to Monte Rosa Therapeutics, Inc.'s net margin of 2.18%. Monte Rosa Therapeutics, Inc.'s return on equity of 8.6% beat Mirum Pharmaceuticals, Inc.'s return on equity of -16.73%.

Monte Rosa Therapeutics, Inc. has a consensus price target of $22.70, signalling upside risk potential of 28.69%. On the other hand Mirum Pharmaceuticals, Inc. has an analysts' consensus of $103.10 which suggests that it could grow by 27.68%. Given that Monte Rosa Therapeutics, Inc. has higher upside potential than Mirum Pharmaceuticals, Inc., analysts believe Monte Rosa Therapeutics, Inc. is more attractive than Mirum Pharmaceuticals, Inc..

Monte Rosa Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Mirum Pharmaceuticals, Inc. has a beta of 0.421, suggesting its less volatile than the S&P 500 by 57.855%.

Monte Rosa Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mirum Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Monte Rosa Therapeutics, Inc. pays -- of its earnings as a dividend. Mirum Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Monte Rosa Therapeutics, Inc. quarterly revenues are $12.8M, which are smaller than Mirum Pharmaceuticals, Inc. quarterly revenues of $133M. Monte Rosa Therapeutics, Inc.'s net income of -$27.1M is lower than Mirum Pharmaceuticals, Inc.'s net income of $2.9M. Notably, Monte Rosa Therapeutics, Inc.'s price-to-earnings ratio is 57.76x while Mirum Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Monte Rosa Therapeutics, Inc. is 7.51x versus 8.72x for Mirum Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -212.1% compared to Monte Rosa Therapeutics, Inc.'s net margin of 21.32%. Monte Rosa Therapeutics, Inc.'s return on equity of 8.6% beat Pfizer Inc.'s return on equity of 10.84%.

Monte Rosa Therapeutics, Inc. has a consensus price target of $22.70, signalling upside risk potential of 28.69%. On the other hand Pfizer Inc. has an analysts' consensus of $28.62 which suggests that it could grow by 14.36%. Given that Monte Rosa Therapeutics, Inc. has higher upside potential than Pfizer Inc., analysts believe Monte Rosa Therapeutics, Inc. is more attractive than Pfizer Inc..

Monte Rosa Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Monte Rosa Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.87% to investors and pays a quarterly dividend of $0.43 per share. Monte Rosa Therapeutics, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Monte Rosa Therapeutics, Inc. quarterly revenues are $12.8M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Monte Rosa Therapeutics, Inc.'s net income of -$27.1M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Monte Rosa Therapeutics, Inc.'s price-to-earnings ratio is 57.76x while Pfizer Inc.'s PE ratio is 14.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Monte Rosa Therapeutics, Inc. is 7.51x versus 2.28x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Zoetis, Inc. has a net margin of -212.1% compared to Monte Rosa Therapeutics, Inc.'s net margin of 30.04%. Monte Rosa Therapeutics, Inc.'s return on equity of 8.6% beat Zoetis, Inc.'s return on equity of 52.95%.

Monte Rosa Therapeutics, Inc. has a consensus price target of $22.70, signalling upside risk potential of 28.69%. On the other hand Zoetis, Inc. has an analysts' consensus of $158.22 which suggests that it could grow by 26.08%. Given that Monte Rosa Therapeutics, Inc. has higher upside potential than Zoetis, Inc., analysts believe Monte Rosa Therapeutics, Inc. is more attractive than Zoetis, Inc..

Monte Rosa Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Zoetis, Inc. has a beta of 0.972, suggesting its less volatile than the S&P 500 by 2.841%.

Monte Rosa Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zoetis, Inc. offers a yield of 1.59% to investors and pays a quarterly dividend of $0.50 per share. Monte Rosa Therapeutics, Inc. pays -- of its earnings as a dividend. Zoetis, Inc. pays out 32.86% of its earnings as a dividend. Zoetis, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Monte Rosa Therapeutics, Inc. quarterly revenues are $12.8M, which are smaller than Zoetis, Inc. quarterly revenues of $2.4B. Monte Rosa Therapeutics, Inc.'s net income of -$27.1M is lower than Zoetis, Inc.'s net income of $721M. Notably, Monte Rosa Therapeutics, Inc.'s price-to-earnings ratio is 57.76x while Zoetis, Inc.'s PE ratio is 21.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Monte Rosa Therapeutics, Inc. is 7.51x versus 5.97x for Zoetis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.